MoonLake Immunotherapeutics’ (MLTX) Buy Rating Reiterated at HC Wainwright

Posted by Geri Gentry on Jul 23rd, 2026

HC Wainwright reiterated their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a research note released on Monday, MarketBeat reports. They currently have a $45.00 price target on the stock. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q2 2026 earnings at ($0.75) EPS, Q3 2026 earnings at ($0.62) EPS, Q4 2026 earnings at ($0.59) EPS, FY2026 earnings at ($2.90) EPS, Q1 2027 earnings at ($0.57) EPS, Q2 2027 earnings at ($0.67) EPS, Q3 2027 earnings at ($0.75) EPS, Q4 2027 earnings at ($0.55) EPS and FY2027 earnings at ($2.54) EPS.

A number of other brokerages have also issued reports on MLTX. Leerink Partners lifted their price target on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an “outperform” rating in a report on Wednesday, July 1st. Needham & Company LLC upped their price objective on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Wolfe Research upgraded shares of MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and increased their price objective for the stock from $12.00 to $24.00 in a report on Monday, March 23rd. BTIG Research reissued a “buy” rating and issued a $30.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 12th. Ten research analysts have rated the stock with a Buy rating, four have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $24.21.

Read Our Latest Report on MLTX

MoonLake Immunotherapeutics Trading Down 5.6%

Shares of MoonLake Immunotherapeutics stock opened at $18.94 on Monday. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75. The business’s fifty day moving average is $18.92 and its two-hundred day moving average is $17.59. The company has a quick ratio of 8.60, a current ratio of 8.60 and a debt-to-equity ratio of 0.39. The firm has a market cap of $1.39 billion, a PE ratio of -4.89 and a beta of 1.04.

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.07). Analysts anticipate that MoonLake Immunotherapeutics will post -3.64 earnings per share for the current year.

Insiders Place Their Bets

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 50,000 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $19.43, for a total transaction of $971,500.00. Following the completion of the sale, the insider directly owned 2,824,551 shares in the company, valued at $54,881,025.93. This represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Da Silva Jorge Santos sold 68,289 shares of the company’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $20.02, for a total value of $1,367,145.78. Following the sale, the chief executive officer owned 2,774,893 shares of the company’s stock, valued at $55,553,357.86. This represents a 2.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 250,000 shares of company stock worth $4,919,138 in the last quarter. 10.40% of the stock is owned by insiders.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of MLTX. Kestra Advisory Services LLC acquired a new stake in MoonLake Immunotherapeutics during the 4th quarter worth approximately $26,000. Bank of America Corp DE raised its holdings in MoonLake Immunotherapeutics by 64.7% in the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after buying an additional 1,781 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in MoonLake Immunotherapeutics by 115.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after buying an additional 3,166 shares in the last quarter. Russell Investments Group Ltd. lifted its position in MoonLake Immunotherapeutics by 45.4% during the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after buying an additional 1,069 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in MoonLake Immunotherapeutics during the fourth quarter worth approximately $47,000. 93.85% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

Neutral Sentiment: HC Wainwright reaffirmed a bullish stance on MoonLake Immunotherapeutics, keeping a Buy rating and $45 price target in place. HC Wainwright Reaffirms Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)
Positive Sentiment: Analysts improved near-term earnings estimates for Q2 2026, Q3 2026, Q4 2026, and Q1 2027, suggesting slightly better expected operating performance in the next several quarters.
Positive Sentiment: FY2026 and FY2027 loss forecasts were also reduced, which may be interpreted as a modest improvement in the company’s longer-term earnings path.
Negative Sentiment: Q3 2027 earnings estimates were cut, and the stock may be under pressure because investors are focusing on the mixed nature of the revisions rather than the Buy rating.

About MoonLake Immunotherapeutics

(Get Free Report)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.